ICD-10 Specific code Q81.2: Epidermolysis bullosa dystrophica
Specific codes in ICD-10 are unique alphanumeric designations used to identify and categorize diseases, disorders, and conditions. They consist of 3-5 characters, including both letters and numbers, that provide a high level of detail and specificity.
Translations
| Language | Translation |
|---|---|
English
|
Epidermolysis bullosa dystrophica |
French
|
Épidermolyse bulleuse dystrophique |
Hierarchical position
| Level | Code | Title | |
|---|---|---|---|
| 1 | XVII | Congenital malformations, deformations and chromosomal abnormalities | |
| 2 | Q80-Q89 | Other congenital malformations | |
| 3 | Q81 | Epidermolysis bullosa | |
| 4 | Q81.2 | Epidermolysis bullosa dystrophica |
Indicated medicines
| Active Ingredient |
|---|
|
Beremagene geperpavec is a gene therapy based on an engineered, replication-defective herpes simplex virus 1 (HSV-1) encoded with COL7A1 gene, addressing the underlying genetic cause of dystrophic epidermolysis bullosa. The HSV-1 vector belongs to the human herpes virus (HHV) family of double-stranded DNA viruses. Upon cutaneous application to the wounds, beremagene geperpavec can transduce both keratinocytes and fibroblasts. |